$CDMOP News
Last published 4y ago
- 4y agoCDMOCDMOPAvid Bioservices to Participate in RBC Global CDMO ConferenceGlobeNewswireTUSTIN, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufa
- 4y agoCDMOCDMOPAvid Bioservices Appoints Michael Alston, Jr. as Vice President, OperationsGlobeNewswireTUSTIN, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufa
- 4y agoCDMOCDMOPAvid Bioservices to Participate in Morgan Stanley 20th Annual Global Healthcare ConferenceGlobeNewswireTUSTIN, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufa
- 4y agoCDMOCDMOPAvid Bioservices Reports Financial Results for First Quarter Ended July 31, 2022 and Recent DevelopmentsGlobeNewswire-- Recorded First Quarter Revenue of $36.7 Million -- -- Signed $41 Million in Net New Business Orders and Ended the Quarter with a Record High Backlog of $157 Million -- -- Facilities and Capabilities Expansions in Mammalian and Cell and Gene Th
- 4y agoCDMOCDMOPAvid Bioservices Appoints Pramthesh (Prem) Patel, Ph.D., as Vice President, Process Development for Mammalian Cell BusinessGlobeNewswireTUSTIN, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufa
- 4y agoCDMOCDMOPAvid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2023 After Market Close on September 6, 2022GlobeNewswireTUSTIN, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnolog
- 4y agoCDMOCDMOPAvid Bioservices Reports Financial Results for Fourth Quarter and Full Fiscal Year Ended April 30, 2022 and Recent DevelopmentsGlobeNewswire-- Recorded Fourth Quarter and Full Fiscal Year Revenue of $31 Million and $120 Million, Respectively -- -- Signed $44 Million in Net New Business Orders and Ended the Quarter with a Record High Backlog of $153 Million -- -- New Cell and Gene T
- 4y agoCDMOCDMOPAvid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2022 After Market Close on June 29, 2022GlobeNewswireTUSTIN, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnolog
- 4y agoCDMOCDMOPAvid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing FacilityGlobeNewswireAD/PD Laboratories Open Exactly Eight Months After Announced Plans to Build Viral Vector Facility Build-Out of Facility's CGMP Manufacturing Suites Continues, Expected to Come Online in Mid-Calendar 2023 TUSTIN, Calif., June 14, 2022 (GLOBE N
- 4y agoCDMOCDMOPAvid Bioservices Announces Further Expansion of Process Development Capacity for Mammalian Cell BusinessGlobeNewswireNew Laboratories Have Potential to Support an Additional $20 Million in Annual Process Development Revenue, Doubling Current Mammalian Cell Process Development Capacity Expansion to Cost Approximately $6 Million with Completion Anticipated by End of C
- 4y agoCDMOCDMOPAvid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech ForumGlobeNewswireTUSTIN, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnolo
- 4y agoCDMOCDMOPAvid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2022 and Recent DevelopmentsGlobeNewswire-- Recorded Third Quarter Revenue of $31.5 Million -- -- Myford South and Viral Vector Facilities Construction Continues On Schedule -- -- Signed $52 Million in Net New Business Orders and Ended the Quarter with a Backlog of $140 Million; Highest
- 4y agoCDMOCDMOPAvid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022GlobeNewswireTUSTIN, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnolo
- 4y agoCDMOCDMOPAvid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North FacilityGlobeNewswireTUSTIN, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufac
- 4y agoCDMOCDMOPAvid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2021 and Recent DevelopmentsGlobeNewswire-- Recorded Second Quarter Revenue of $26.1 Million -- -- Initiated Strategic Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy -- -- Signed $36 Million in New Business Orders and Ended the Quarter with a
- 4y agoCDMOCDMOPAvid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2022 After Market Close on December 7, 2021GlobeNewswireTUSTIN, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnolog
- 5y agoCDMOCDMOPAvid Bioservices Appoints Elie G. Hanania, Ph.D., as Vice President, Process Development, Viral Vector TechnologiesGlobeNewswireTUSTIN, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufac
- 5y agoCDMOCDMOPAvid Bioservices to Join S&P SmallCap 600 IndexGlobeNewswireTUSTIN, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufac
- 5y agoCDMOCDMOPAvid Bioservices Announces Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene TherapyGlobeNewswireLeverages Established Track Record of Excellence in Biologics CGMP Manufacturing to Address the Rapidly Growing Cell and Gene Therapy Market World-Class Viral Vector Development and Manufacturing Facility Being Built in Orange County, CA Appoints
- 5y agoCDMOCDMOPAvid Bioservices Appoints Matthew Kwietniak as Chief Commercial OfficerGlobeNewswireTUSTIN, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufac
- 5y agoCDMOCDMOPAvid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent DevelopmentsGlobeNewswire-- Recorded First Quarter Revenue of $30.8 Million -- -- Achieved Fifth Consecutive Quarter of Operational Profitability -- -- Signed $23 Million in New Business Orders and Ended the Quarter with a Backlog of $110 Million -- -- Phase 1 a
- 5y agoCDMOCDMOPAvid Bioservices to Participate at Upcoming Investor ConferencesGlobeNewswireTUSTIN, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnolo
- 5y agoCDMOCDMOPAvid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2022 After Market Close on September 8, 2021GlobeNewswireTUSTIN, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnolo
- 5y agoCDMOCDMOPAvid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of DirectorsGlobeNewswireTUSTIN, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufact
- 5y agoCDMOCDMOPAvid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent DevelopmentsGlobeNewswire-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 -- -- Signed Approximately $148 Million in New Business Orders and Achi
- 5y agoCDMOCDMOPAvid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021GlobeNewswireTUSTIN, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufact
- 5y agoADCTCDMOCDMOPAvid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics' ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)GlobeNewswireTUSTIN, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality developme
- 5y agoCDMOCDMOPAvid Bioservices Announces Completion of Redemption of Series E Convertible Preferred StockGlobeNewswireTUSTIN, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
- 5y agoCDMOCDMOPHGENHumanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA FilingBusiness WireBURLINGAME, Calif. & TUSTIN, Calif.--(BUSINESS WIRE)--Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab™, Humanigen’s therapeutic candidate in development for COVID-19. Lenzilumab is an anti-human granulocyte macropha ...
- 6y agoCDMOCDMOPAvid Bioservices Announces Move to Virtual-Only Annual Meeting of Stockholders on October 20, 2020GlobeNewswireTUSTIN, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), today announced that it will hold its 2020 Annual Meeting of Stockholders (the “Annual...
- 6y agoCDMOCDMOPAvid Bioservices to Participate in 18th Annual Morgan Stanley Global Healthcare ConferenceGlobeNewswireTUSTIN, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
- 6y agoCDMOCDMOPAvid Bioservices Reports Financial Results for First Quarter Ended July 31, 2020 and Recent DevelopmentsGlobeNewswire-- Recorded First Quarter Revenue of $25.4 Million -- -- Signed Three New Customers and Project Expansion Orders with Current Customers for $20 Million -- -- Backlog of $60 Million at Quarter-End --...
- 6y agoCDMOCDMOPAvid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred StockGlobeNewswireTUSTIN, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
- 6y agoCDMOCDMOPAvid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral AntibodyGlobeNewswireTUSTIN, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
- 6y agoCDMOCDMOPAvid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2021 After Market Close on September 1, 2020GlobeNewswireTUSTIN, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
- 6y agoOGENCDMOCDMOPOragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus VaccineBusiness WireTAMPA, Fla. & TUSTIN, Calif.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) and Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), today announced that the companies have entered into a process development and drug substance manufacturing agreement. Under terms of the agreement, Avid will provide Oragenics with analytical method development, process development and drug substance manufa ...
- 6y agoCDMOCDMOPAvid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001GlobeNewswireTUSTIN, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
- 6y agoCDMOCDMOPAvid Bioservices and Argonaut Manufacturing Services Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Process Development, Drug Substance Manufacturing and Drug Product Parenteral ManufacturingGlobeNewswireTUSTIN, Calif. and CARLSBAD, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing...
- 6y agoCDMOCDMOPAvid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2020 and Recent DevelopmentsGlobeNewswire-- Appointed Nicholas Green as President and Chief Executive Officer -- -- Recorded Fourth Quarter Revenue of $12.6 Million and Annual Revenue of $59.7 Million -- -- Signed $23 Million in Business...
- 6y agoCDMOCDMOPAvid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2020 After Market Close on June 30, 2020GlobeNewswireTUSTIN, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
- 6y agoCDMOCDMOPAvid Bioservices Names Nicholas Green as President and Chief Executive OfficerGlobeNewswireTUSTIN, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
- 6y agoCDMOCDMOPAvid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred StockGlobeNewswireTUSTIN, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
- 6y agoCDMOCDMOPAvid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Solution for Cell Line and Process Development through Commercial ManufacturingGlobeNewswireTUSTIN, Calif. and MORGAN HILL, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing...
- 6y agoCDMOCDMOPAvid Bioservices Announces Appointment of Two Senior Directors of Business Development with Responsibility for North America, Europe and AsiaGlobeNewswireTUSTIN, Calif., April 13, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
- 6y agoCDMOCDMOPAvid Bioservices Receives Five 2020 CMO Leadership AwardsGlobeNewswireCompany Honored for Capabilities, Expertise, Reliability, Compatibility, and Service in the Contract Development and Manufacturing Industry Named 2020 CMO Leadership Award Champion in Categories of...
- 6y agoCDMOCDMOPAvid Bioservices Reports Financial Results for Third Quarter Fiscal 2020 and Recent DevelopmentsGlobeNewswire-- Recorded Third Quarter Revenue of $13.6 Million -- -- Signed New Customer and Project Expansion Orders with Current Customers for $20 Million -- -- Adjusting Fiscal 2020 Projected Revenue to $55...
- 6y agoCDMOCDMOPAvid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred StockGlobeNewswireTUSTIN, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
- 6y agoCDMOCDMOPAvid Bioservices Appoints Timothy Compton as Chief Commercial OfficerGlobeNewswireTUSTIN, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
- 6y agoCDMOCDMOPAvid Bioservices Reports Financial Results for Second Quarter Fiscal 2020 and Recent DevelopmentsGlobeNewswire-- Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18% -- -- Fiscal 2020 Projected Revenue of $64 to $67 Million Reaffirmed -- -- Launched Expanded Process Development...
- 6y agoCDMOCDMOPAvid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred StockGlobeNewswireTUSTIN, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...